Biocon signs MoU with Australia's Deakin University
Our Corporate Bureau
08 June 2007
The MoU includes establishing the Deakin Research Institute in Bangalore and the joint development of a mammalian cell bio-processing facility at Geelong in Victoria, Australia.
Moreover, through its metabolic research unit, Deakin will undertake research on metabolic diseases on behalf of Biocon.
To manage the high levels of innovation required in bio pharmaceuticals, Biocon supplements its R&D efforts by working with academic institutions and biotechnology companies around the world.
The tie-up with Deakin, which has a proven research capability in a multi- disciplinary environment, will enable Biocon to utilise this expertise in mammalian cell bio-processing and metabolic diseases.
"The signing of this MOU will formally initiate collaboration in research and education between Biocon and Deakin University, Australia," said Kiran Mazumdar-Shaw, chairman and managing director, Biocon. "This partnership will provide valuable access to a world of medical knowledge and scientific training, together with opportunities for exchange of scientists to facilitate projects in areas of mutual interest," she added.